| Jun 28 |
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) most popular amongst retail investors who own 54% of the shares, institutions hold 35%
|
| Jun 17 |
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
|
| Jun 14 |
Aurinia Announces 2024 Annual General Meeting Results
|
| Jun 8 |
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO For Now
|
| Jun 5 |
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
|
| Jun 4 |
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
|
| Jun 3 |
Aurinia Provides Update on Proxy Statement
|
| May 30 |
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
|
| May 26 |
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 64%, as stock drops 9.5% this past week
|
